title: Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study.
abstract: BACKGROUND
  The aim of this randomized study was to investigate the effect of seven-day high-dose atorvastatin therapy on the incidence of peri-procedural myocardial infarction (PMI) in patients receiving long-term statin therapy.
  
  
  METHODS
  The patients with stable angina receiving statin therapy and referred for percutaneous coronary intervention (PCI) were randomized (ratio 1:1) to a 7-day pre-treatment with atorvastatin of 80 mg daily and subsequent PCI (Atorvastatin group), or immediate PCI (Control group). The incidence of PMI was based on serum concentration of creatine kinase myocardial band (CK-MB) mass and troponin I (TnI), which were measured prior to and between 16 and 24h post PCI. The values were considered as positive if they were elevated ≥ 3 times the upper limit normal.
  
  
  RESULTS
  We randomized 202 patients (male 67%, 65.5 ± 9.2 years; 100 vs. 102 pts.). There were no significant differences in the baseline characteristics among the randomized groups. The incidence of PMI, based on post-interventional release of TnI and/or CK-MB mass was 15% in the Atorvastatin group vs. 14% in the Control group (p=0.80). One patient (3%) in Atorvastatin group suffered from MI between randomization and PCI.
  
  
  CONCLUSIONS
  These results suggest that 7-day pre-PCI therapy with high-dose atorvastatin did not reduce the occurrence of PMI in patients receiving chronic statin therapy.
authors.affiliation: Department of Cardiology, 2nd Medical School of Charles University and University Hospital Motol, Prague, Czech Republic. Electronic address: zejada@seznam.cz.
authors.forename: David
authors.initials: D
authors.lastname: Zemánek
authors.forename: Marian
authors.initials: M
authors.lastname: Branny
authors.forename: Lucie
authors.initials: L
authors.lastname: Martinkovičová
authors.forename: Petr
authors.initials: P
authors.lastname: Hájek
authors.forename: Martin
authors.initials: M
authors.lastname: Malý
authors.forename: David
authors.initials: D
authors.lastname: Tesař
authors.forename: Pavol
authors.initials: P
authors.lastname: Tomašov
authors.forename: Josef
authors.initials: J
authors.lastname: Veselka
mesh_terms: D000368:Aged; D000069059:Atorvastatin; D004334:Drug Administration Schedule; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000517:prevention & control*; D062645:Percutaneous Coronary Intervention; D011183:Postoperative Complications / Q000453:epidemiology* / Q000517:prevention & control*; D011758:Pyrroles / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin
keywords: Atorvastatin pretreatment; Percutaneous coronary intervention; Periprocedural myocardial infarction; Statin